Brief: Mabion Says Mylan Ireland Terminates Cooperation Deal

Mabion SA

18/11/2021 07:51

Nov 18 (Reuters) - Mabion SA  MABP.WA :
    * SAID ON WEDNESDAY COMPANY HAS RECEIVED TERMINATION OF ITS
NOV
2016 DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FROM MYLAN
IRELAND
    * TERMINATION CARRIES 90-DAY NOTICE PERIOD
    * MYLAN IRELAND WAS NON-EXCLUSIVE DISTRIBUTION PARTNER FOR
MABIONCD20 DRUG IN SELECTED COUNTRIES INCLUDING AUSTRALIA, NEW
ZEALAND, MEXICO, IN CENTRAL AMERICA, SOUTH AFRICA, SOUTH-EAST
ASIA
    * KEY SALES RIGHTS FOR EUROPEAN UNION AND UNITED STATES
BELONGED
AND BELONG TO COMPANY AND MAY BECOME COMMERCIALISED IN THE
FUTURE DEPENDING ON COMPANY'S NEEDS AND DECISION
    * TERMINATION CURRENTLY CARRIES NO NEED FOR PAYMENT OR
ADDITIONAL
FINANCIAL OBLIGATIONS BY COMPANY
    * COMPANY NOW HAS FULL NEEDED FLEXIBILITY IN COMMERCIALISING
MABION CD20 ON ALL MARKETS WHICH MAY HAVE POSITIVE IMPACT ON
PROCESS OF SEEKING STRATEGIC INVESTOR BY COMPANY

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM38HN7Da
 Further company coverage:  MABP.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))